SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein

COVID-19 Nucleocapsid Research.
1/1
Price:
Size:
Number:

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 製品情報

純度
> 90 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
活性
Testing in progress
タンパク質の構築
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (YP_009724397.2(335Gly/Ala)) (Met1-Ala419) was expressed with a polyhistidine tag at the C-terminus.
発現ホスト
Baculovirus-Insect Cells
2019-nCoV
予測N末端
Met 1
分子量
The recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (His tag) consists of 430 amino acids and predicts a molecular mass of 47.08 kDa.
バッファー
Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0, 10%glycerol
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
配送
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
安定性 & 保存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
再構成
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 画像

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: 別名

coronavirus NP Protein, 2019-nCoV; coronavirus Nucleocapsid Protein, 2019-nCoV; coronavirus Nucleoprotein Protein, 2019-nCoV; cov np Protein, 2019-nCoV; ncov NP Protein, 2019-nCoV; NCP-CoV Nucleocapsid Protein, 2019-nCoV; novel coronavirus NP Protein, 2019-nCoV; novel coronavirus Nucleocapsid Protein, 2019-nCoV; novel coronavirus Nucleoprotein Protein, 2019-nCoV; np Protein, 2019-nCoV; nucleocapsid Protein, 2019-nCoV; Nucleoprotein Protein, 2019-nCoV

Coronavirus Nucleocapsid 背景情報

Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
参考文献
    1. 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12.
    2. Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6.
    3. Li W. et al., 2005, Science. 309 (5742): 1864-8.
  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
    Author
    Randad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;
    Year
    2020
    Journal
    medRxiv
  • Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
    Author
    Sun, B;Feng, Y;Mo, X;Zheng, P;Wang, Q;Li, P;Peng, P;Liu, X;Chen, Z;Huang, H;Zhang, F;Luo, W;Niu, X;Hu, P;Wang, L;Peng, H;Huang, Z;Feng, L;Li, F;Zhang, F;Li, F;Zhong, N;Chen, L;
    Year
    2020
    Journal
    Emerg Microbes Infect
  • SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity
    Author
    Phipps, WS;SoRelle, JA;Li, QZ;Mahimainathan, L;
    Year
    2020
    Journal
    medRxiv
    Application
    IgM testing
  • Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection
    Author
    Simon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;
    Year
    2020
    Journal
    Research Square
  • SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients
    Author
    Lei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;
    Year
    2020
    Journal
    Influenza Other Respir Viruses
  • SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence
    Author
    den Hartog, G;Schepp, R;Kuijer, M;GeurtsvanKessel, C;van Beek, J;Rots, N;Koopmans, M;van der Klis, F;van Binnendijk, R;
    Year
    2020
    Journal
    medRxiv
  • COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium Injury
    Author
    Wang, Z;Yang, X;Zhou, Y;Sun, J;Liu, X;Zhang, J;Mei, X;Zhong, J;Zhao, J;Ran, P;
    Year
    2020
    Journal
    Am. J. Respir. Crit. Care Med.
    Application
    neutralization test
  • SARS-CoV-2 surveillance for a non-human primate breeding research facility
    Author
    Yee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O'Connor, DJ;Miller, CJ;Roberts, JA;
    Year
    2020
    Journal
    J. Med. Primatol.
  • A rapidly adaptable biomaterial vaccine for SARS-CoV-2
    Author
    Langellotto, F;Seiler, B;Yu, J;Cartwright, M;White, D;Yeager, C;Super, M;Doherty, E;Barouch, D;Mooney, D;
    Year
    2020
    Journal
    bioRxiv
カートに追加しました カートに追加しませんでした カートを更新しています。少々お待ちください U.S.A.